Masimo Corp Stock Price, News & Analysis

Masimo (MASI) has released preliminary financial results for Q4 and full-year 2024, along with 2025 guidance. Q4 2024 consolidated revenue is expected to reach $601 million, showing 9% growth. This includes healthcare revenue of $368 million (+8%) and non-healthcare revenue of $232 million (+11%).

For full-year 2024, consolidated revenue is anticipated at $2,094 million (+2%), with healthcare revenue at $1,395 million (+9%) and non-healthcare revenue at $699 million (-10%). Non-GAAP earnings per diluted share is expected to exceed $4.10, reaching the high end of previous guidance.

Looking ahead to 2025, Masimo projects healthcare revenue between $1,500-1,530 million (8-11% growth), Non-GAAP operating profit of $398-406 million (26.5% margin), and Non-GAAP earnings per diluted share of $4.90-5.10. The company is excluding Sound United from non-GAAP measures due to ongoing separation plans.

Masimo (MASI) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company's management will present on Thursday, January 16, 2025, at 10:30 a.m. Pacific time. Investors and interested parties can access a live webcast of the presentation through Masimo's website. For those unable to attend the live session, a replay will be made available on the company's website following the presentation.

Masimo (NASDAQ: MASI) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 8:30 a.m. Eastern time. Interested parties can access a live webcast of the presentation through the company's website at www.masimo.com. The company will also make a replay of the webcast available after the live presentation concludes.

Masimo (NASDAQ: MASI) has announced its participation in the upcoming Jefferies London Healthcare Conference. The presentation is scheduled for Thursday, November 21, 2024, at 8:30 a.m. GMT. Interested parties can access a live webcast of the presentation through Masimo's website. For those unable to attend the live session, a replay will be made available on the company's website following the presentation.

Masimo (NASDAQ: MASI) has announced its participation in the upcoming Stifel 2024 Healthcare Conference. The company's management will present on Monday, November 18, 2024 at 11:30 a.m. Eastern Time. Interested parties can access a live webcast of the presentation through Masimo's website. A replay option will be available after the live presentation concludes.

Masimo (MASI) reported Q3 2024 financial results with consolidated revenue of $504.6 million, including healthcare revenue of $343.3 million (up 11.5%) and non-healthcare revenue of $161.3 million. The company shipped 60,500 noninvasive technology boards and instruments. GAAP net income was $9.8 million ($0.18 per diluted share), while non-GAAP net income reached $52.9 million ($0.98 per diluted share). The company updated its FY2024 guidance, projecting consolidated revenue between $2,075-$2,105 million and non-GAAP earnings per diluted share of $3.95-$4.10.

Vanderbilt University Medical Center (VUMC) is implementing Masimo Radius VSM™ wireless vital signs monitoring system in its Emergency Department to address ER congestion. The pilot program enables continuous monitoring of patients in hallway beds, emergency service offload areas, and waiting rooms, where monitoring is typically periodic. The system, integrated with Patient SafetyNet™, allows clinicians to remotely monitor vital signs in real time from centralized stations, offering measurements including pulse oximetry, blood pressure, temperature, respiration rate, and ECG. The implementation aims to transform traditionally unmonitored spaces into areas of proactive patient care, potentially improving patient throughput and prioritization.

Masimo (NASDAQ: MASI) has announced it will release its third quarter 2024 financial results on Tuesday, November 5, 2024, after the market closes. The results will cover the period ended September 28, 2024. A conference call and webcast to discuss the results will begin at 1:30 p.m. PT (4:30 p.m. ET) on the same day.

The call will be hosted by Michelle Brennan, interim Chief Executive Officer, Micah Young, Executive Vice President and Chief Financial Officer, and Bilal Muhsin, Chief Operating Officer. Interested parties can register for the conference call to receive dial-in details and a registrant ID. A replay of the webcast and conference call will be available shortly after the conclusion and archived on Masimo's website.

Masimo (Nasdaq: MASI) has announced significant leadership changes and business updates. Michelle Brennan, a current board member, has been appointed as interim CEO following Joe Kiani's resignation. The company has also officially appointed Darlene Solomon and Bill Jellison to the Board. Masimo has engaged Korn Ferry to assist in CEO succession planning.

The Board remains committed to reviewing strategic alternatives for both consumer audio and healthcare businesses, with Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as legal advisor. Masimo has reaffirmed its non-GAAP financial guidance for the third quarter of 2024, previously provided on August 6, 2024.

Michelle Brennan, with over 30 years of experience at Johnson & Johnson, expressed excitement about the opportunity to help Masimo continue its growth and innovation focus. The company's management team emphasized strong business momentum and future growth prospects.